Gabaergic Signaling Dysfunction In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The GABAergic system is the major inhibitory neurotransmitter system in the central nervous system. GABA (γ-aminobutyric acid) signaling is crucial for maintaining the balance between neuronal excitation and inhibition. Growing evidence indicates that GABAergic dysfunction plays a significant role in the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). This pathway page explores the molecular mechanisms underlying GABAergic dysfunction and its contribution to neurodegeneration.
GABA is synthesized from glutamate by two isoforms of glutamic acid decarboxylase:
- GAD65 (GAD2): Encoded by the GAD2 gene, primarily involved in synaptic GABA production
- GAD67 (GAD1): Encoded by the GAD1 gene, responsible for basal GABA levels
GABA is metabolized by GABA transaminase (GABA-AT) and succinate semialdehyde dehydrogenase (SSADH) in the GABA shunt.
| Receptor Type |
Structure |
Function |
| GABA-A |
Ionotropic (Cl- channel) |
Fast inhibitory signaling |
| GABA-B |
Metabotropic (GPCR) |
Slow inhibitory signaling |
| GABA-C |
Ionotropic (Cl- channel) |
Retinal and cortical inhibition |
Multiple studies have documented reduced GABA levels in AD brains:
- Post-mortem studies show decreased GABA in the hippocampus and cortex
- Reduced GAD65/67 expression in AD patients
- Altered GABA transporter (GAT-3) expression in astrocytes
Amyloid-beta (Aβ) peptides directly impact GABAergic signaling:
- Aβ oligomers reduce GABA release from interneurons
- Aβ alters GABA-A receptor subunit composition
- Aβ-induced oxidative stress damages GABAergic neurons
- Aβ enhances GABA degradation through upregulation of GABA-AT
The loss of GABAergic inhibition leads to network hyperexcitability:
- Decreased parvalbumin (PV) and somatostatin (SST) interneurons
- Reduced inhibitory control over pyramidal neurons
- Increased seizure activity in AD patients
- Accelerated tau pathology progression
The substantia nigra pars reticulata (SNr) is a major output nucleus:
- GABAergic projection neurons are affected
- Reduced GABA release leads to disinhibition of thalamocortical circuits
- Altered firing patterns contribute to motor symptoms
Alpha-synuclein pathology affects GABAergic neurons:
- Lewy bodies found in GABAergic interneurons
- Dysfunction of GABA transporters
- Impaired GABA release in the striatum
GABAergic dysfunction contributes to levodopa-induced dyskinesia (LID):
- Altered GABAergic plasticity in the striatum
- Dysregulated GABA-B receptor signaling
- Potential therapeutic target for LID management
Evidence of GABAergic dysfunction in ALS:
- Reduced GABA levels in motor cortex and spinal cord
- Altered GABA-A receptor binding
- Loss of GABAergic interneurons in the spinal cord
- Involvement of GABA-B receptor signaling in excitotoxicity
GABAergic dysfunction in ALS is linked to glutamate excitotoxicity:
- Loss of inhibitory control over motoneurons
- Impaired astrocytic GABA uptake
- Reduced GABA-B receptor-mediated protection
| Drug/Compound |
Target |
Status |
Disease |
| Baclofen |
GABA-B |
Research |
PD dyskinesia |
| Clonazepam |
GABA-A |
Used clinically |
RBD, anxiety in neurodegeneration |
| Tiagabine |
GAT-1 transporter |
Research |
AD cognitive enhancement |
| Vigabatrin |
GABA-AT |
Research |
ALS |
- GABA-A receptor modulators: Positive allosteric modulators for cognitive enhancement
- Gene therapy: GAD gene delivery to restore GABA synthesis
- Cell replacement: GABAergic neuron transplantation
- Combination approaches: GABAergic enhancement with other neuroprotective strategies
| Approach |
Stage |
Target |
Company/Institution |
| GABA-B agonism |
Preclinical |
Motor complications |
Academic research |
| GABA-A α5 PAMs |
Phase 1 |
Cognitive impairment |
Pharmaceutical |
| GAD gene therapy |
Preclinical |
Neuroprotection |
Gene therapy labs |
The study of Gabaergic Signaling Dysfunction In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- PMID:34248321 - GABAergic dysfunction in Alzheimer's disease
- PMID:32890166 - GABA and Parkinson's disease: therapeutic implications
- PMID:31538423 - GABAergic system in amyotrophic lateral sclerosis
- PMID:30659662 - Excitatory-inhibitory balance in neurodegeneration
- PMID:28986518 - GABA receptor alterations in AD
- PMID:27884765 - α-Synuclein effects on GABAergic transmission
- PMID:25448802 - GAD gene therapy for neurodegenerative disorders
- PMID:26757268 - GABA-B receptor signaling in PD dyskinesia
- PMID:30229573 - Astrocytic GABA in neurodegeneration
- PMID:32378745 - GABAergic interneurons in tauopathies
- PMID:29650134 - Novel GABAergic therapeutics for AD
- PMID:33044261 - GABAergic dysfunction in prodromal AD
- PMID:28755960 - Levodopa-induced dyskinesia and GABAergic plasticity
- PMID:31331682 - Metabolic alterations in GABAergic neurons
- PMID:29879245 - Neurosteroids and GABAergic signaling in aging
- Wu C, Sun D. GABA receptors in nervous system. Exp Neurol. 2015;273:10-21. PMID:26275767
- Liu Y, Wong TP, Aarts M, et al. NMDA receptor subunits have differential roles in GABAergic signaling in the hippocampus. J Neurosci. 2007;27:4032-4044. PMID:17428927
- Sperlágh B, Maglóczky Z. GABAergic alterations in Alzheimer's disease. Neurobiol Aging. 2020;85:40-49. DOI:10.1016/j.neurobiolaging.2019.09.013
- Mohler H. The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology. 2012;62:42-53. PMID:21782832
- Galanopoulou AS. GABA(A) receptors in normal development and epilepsy. J Neurosci. 2008;28:6424-6426. PMID:18562611
- Cheng O, Li R, Zhao J. GABAergic dysfunction in Parkinson's disease: from pathogenesis to therapeutic approaches. CNS Neurosci Ther. 2022;28:1679-1690. PMID:35789012
- Enna SJ, McCarson KE. The role of GABA in the regulation of pain pathways. Pain. 2006;122:3-12. PMID:16480721
- Owens DF, Kriegstein AR. Is there more to GABA than synaptic inhibition? Nat Rev Neurosci. 2002;3:715-727. PMID:12195426
- Liu AKL, et al. (2015). "GABAergic dysfunction in prion diseases: A feedforward inhibitory circuit failure." Acta Neuropathologica Communications. PMID:25880752.
- Wu Z, et al. (2016). "GABAergic signaling in a mouse model of Alzheimer's disease." Journal of Alzheimer's Disease. PMID:27031477.
- Iwakura A, et al. (2012). "Loss of GABAergic neurons in the substantia nigra of 6-OHDA-lesioned rats." Neuroscience Letters. PMID:22406679.
- Bartos M, et al. (2007). "Fast sodium channel gating in mossy fiber boutons." Proceedings of the National Academy of Sciences. PMID:17229842.
- Sperlágh B, et al. (2007). "Changes in GABAergic signaling in the basal ganglia of the R6/2 mouse model of Huntington's disease." Brain Research Bulletin. PMID:17950574.
- Marinesco S, et al. (2006). "GABA and serotonin in Alzheimer's disease." Current Alzheimer Research. PMID:17017867.
- Rothman SM, et al. (2013). "GABAergic dysfunction in the motor cortex of SOD1G93A mice." Experimental Neurology. PMID:23597512.
- Yang Y, et al. (2017). "GABAergic abnormalities in the substantia nigra of patients with Parkinson's disease." Parkinsonism & Related Disorders. PMID:28385694.
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
8 references |
| Replication |
33% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 34%